Dynavax Technologies Corporation (NASDAQ: DVAX) revealed that it has received Marketing Authorization (MA) for HEPLISAV B. DVAX has been awarded this MA after the positive reviews of EMA CHMP. CHMP has provided the consent and suggested the HEPLISAV B after assessing the optimistic benefits of the vaccine and after seeing the outcomes of three Phase III experimental studies.

HEPLISAV B is the cure against the hepatitis B infection in grown person. HEPLISAV-B is an adult hepatitis B vaccine that blends hepatitis B surface antigen with the patented Toll-like Receptor (TLR) 9 agonist adjuvant CpG 1018 of DVAX to boost the immune response. Dynavax possesses international business entitlements to HEPLISAV-B.

Hepatitis B is a viral illness of the liver that can grow into a recurring illness and caused cirrhosis, liver cancer, & death. The hepatitis B virus is 50 to 100 times more contagious than HIV and the continuously world is facing a rise in the cases of hepatitis B. Nearly 200 million folks all around the globe have been affected by this deadly disease.

But thanks to DVAX, patients have a new hope to live longer if they are experiencing the disease. The firm is looking forward to introducing the vaccine in Europe and it is anticipating that the launch will be held in the following year. The MA awarded by EC is effective in all EU and EFTA states. HEPLISAV-B is now authorized in the U.S. and EU.